Introduction:
MaSTherCell SA announced new manufacturing facility in Belgium for cell and gene therapy products.
Features:
The company has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium.
The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially approved cell and gene therapy products.
This new site will significantly expand MaSTherCell’s current European manufacturing capacity.
MaSTherCell will continue to use its existing site for both industrialisation and early to mid-stage clinical programs.
In addition, the facility will be included with industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide cell and gene therapy community.
The manufacturing facility is expected to be operational in early 2021.
This state-of-the-art plant will create several hundred jobs and Belgian expertise needs to train the teams.
Specifications:
| Name | MaSTherCell SA |
| Type | New Construction |
| Parties Involved | MaSTherCell SA |
| Schedule | Scheduled to be operational in 2021 |
